This content is machine translated Diabetes mellitus Biomarker-associated clustering for improved treatment management. Phenotyping and subclassification of diabetic patients is becoming increasingly important to provide patient-adapted treatment options. Meanwhile, there are several cluster analyses that could reveal certain specific patterns of patient characteristics.…
View Post 3 min This content is machine translated Sponsored Content RYBELSUS® – Semaglutide as the world’s first and only oral GLP-1 analogue People with type 2 diabetes have too little endogenous GLP-1 (glucagon-like peptide 1) or its effect is reduced. Semaglutide, which mimics natural GLP-1, can compensate for this.1,2 It lowers blood…
View Post 6 min This content is machine translated Chronic wounds Local therapy of poorly healing, infectious wounds Pressure ulcers, diabetic foot syndrome and venous leg ulcers are the most common causes of chronic wounds and are becoming an increasingly important topic in dermatology. W.A.R and PEDIS scores…
View Post 4 min This content is machine translated Type 2 diabetes: Update 2021 SGLT-2 inhibitors and GLP-1-RA: added value to treatment. Early detection and follow-up are critical for the management of type 2 diabetes mellitus. This is more relevant than ever in the current COVID 19 pandemic. The goals of modern diabetes…
View Post 14 min This content is machine translated Focus on diabetes and heart New studies and new recommendations Study data in recent years have highlighted the enormous extent to which type 2 diabetes mellitus (T2D) promotes the development of cardiovascular disease. In addition, it became clear that certain…
View Post 3 min This content is machine translated Heart failure SGLT-2 inhibitors – great therapeutic potential in HFrEF patients. In addition to the SGLT-2 inhibitor dapagliflozin, which was also approved by Swissmedic last July for the treatment of heart failure (HFrEF) in non-diabetics, another member of this drug class,…
View Post 3 min This content is machine translated Type 2 diabetes: insulin therapy - quo vadis? Basic insulin with once-weekly injection convinces An ultra-long-acting insulin analogue that only needs to be injected once a week is currently in development. The results of the clinical studies to date are promising. Insulin Icodec has…
View Post 1 min This content is machine translated Continuing education series on type 2 diabetes (2021) Dia-Month Club Module 1: SGED Recommendations The digital and CME-certified continuing education series “Dia-Month Club” on type 2 diabetes started on April 30.Our expert, Prof. Roger Lehmann (University Hospital Zurich), explains in the first module the… CME-Test
View Post 1 min This content is machine translated Continuing education series on type 2 diabetes (2021) Dia-Month Club Module 3: LDL cholesterol On June 25, the third module of the Dia-Month Club took place, focusing on an often underestimated risk factor, LDL cholesterol. Our expert, Prof. Isabella Sudano (University Hospital Zurich), presented… CME-Test
View Post 1 min This content is machine translated Continuing education series on type 2 diabetes (2021) Dia-Month Club Module 4: Heart In the fourth module of the Dia-Month Club on September 3, Prof. Christian Müller (University Hospital Basel) used current data to show how modern diabetes management decisively reduces the patient’s… CME-Test
View Post 1 min This content is machine translated Continuing education series on type 2 diabetes (2021) Dia-Month Club Module 5: Kidney On October 26, the fifth module of the Dia-Month Club was held on the topic of kidneys. Our expert, PD Dr. Michael Mayr (University Hospital Basel), explained the practical guardrails… CME-Test
